Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
2 November 2017
ORYZON to participate in three scientific meetings on CNS
31 October 2017
ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001
9 October 2017
ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS
11 September 2017
Oryzon Genomics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference and at the 17th Annual Biotech in Europe Forum
28 July 2017
ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
24 July 2017
ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017)
20 July 2017
ORYZON to Regain Rights to ORY-1001 (RG6016)
31 May 2017
Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference
16 May 2017
Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department
9 May 2017
ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »